SAINT LAURENT, Quebec, May 14, 2021 (GLOBE NEWSWIRE) — IntelGenx Technologies Corp. (TSX-V: IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today reported that the previously announced US$12,346,300 investment in IntelGenx by ATAI Life Sciences AG (“atai”) has been completed. As a result of the investment, atai now holds approximately 25% of the issued and outstanding common…


Previous articlePharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson’s Disease
Next articleThe Impact of Specific Genes on Cannabis Use Disorder